List of works - Tiziano Barbui

A Polycythemia Vera Updated: Diagnosis, Pathobiology, and Treatment.

scientific article

A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera.

scientific article published on 16 August 2014

A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis

scientific article published on 14 October 2020

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea

scientific article

A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms

scientific article

A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study

scientific article

Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study

scientific article (publication date: April 2005)

Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome

scientific article

Antiphospholipid Syndrome: Definition and Treatment ⬇️

scientific article published on April 1, 2003

Antiphospholipid antibodies and pregnancy.

scientific article

Antiphospholipid antibodies and thrombosis: strength of association

scientific article

Antiphospholipid syndrome: clinical and diagnostic utility of laboratory tests

scientific article

Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group

scientific article

Bleeding and thrombosis in acute leukemia: what does the future of therapy look like?

scientific article

Chronic myeloproliferative disorders

scientific article (publication date: 2003)

Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study

scientific article

Comments on pre-fibrotic myelofibrosis and how should it be managed

scientific article published on 07 March 2019

Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group

scientific article

Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients

scientific article

Efficacy and safety of low-dose aspirin in polycythemia vera

scientific article (publication date: 8 January 2004)

Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases.

scientific article

European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 2012;97(3):360-5--comment

scientific article published on March 2012

European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia.

scientific article

Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome

scientific article

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

scientific article published on 07 January 2021

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

scientific article

Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group

scientific article published on 01 November 2019

Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study

scientific article

Indications for lowering platelet numbers in essential thrombocythemia

scientific article

Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3.

scientific article

Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative

scientific article published on 22 June 2019

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

scientific article

Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera

scientific article (publication date: May 2005)

Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera

scientific article (publication date: 15 March 2007)

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

scientific article

Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature

scientific article

Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic review

scientific article published on 27 January 2018

Molecular characterization of a new recombination of the SIL/TAL-1 locus in a child with T-cell acute lymphoblastic leukaemia

scientific article (publication date: September 2002)

Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management

scientific article

Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management

scientific article published on 09 November 2018

Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.

scientific article published on February 2004

Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.

scientific article

Prevalence and risk factors for Pulmonary Hypertension associated with chronic Myeloproliferative Neoplasms

scientific article published on 01 November 2020

Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients.

scientific article

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

scientific article

Risk-adapted therapy in essential thrombocythemia and polycythemia vera

scientific article

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.

scientific article

Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study

scientific article published on 29 May 2019

Second cancers in MPN: Survival analysis from an international study

scientific article published on 22 December 2019

Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients

scientific article published on 07 June 2019

Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases

scientific article published on 29 November 2019

The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera

scientific article published on 17 May 2011

The European LeukemiaNet: achievements and perspectives

scientific article

The haematocrit and platelet target in polycythemia vera

scientific article (publication date: 2007)

The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both?

scientific article published on April 2004

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

scientific article

Transplant-finalized salvage of adult acute lymphoblastic leukemia: results of a mitoxantrone- and methotrexate-based regimen in 36 patients

scientific article

Treatment indications and choice of a platelet-lowering agent in essential thrombocythemia

scientific article

What is the standard treatment in essential thrombocythemia

scientific article (publication date: August 2002)

When and how to treat essential thrombocythemia

scientific article (publication date: 7 July 2005)

List of works by Tiziano Barbui

A Polycythemia Vera Updated: Diagnosis, Pathobiology, and Treatment.

A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera.

A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea

A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms

A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study

Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study

Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome

Antiphospholipid Syndrome: Definition and Treatment ⬇️

Antiphospholipid antibodies and pregnancy.

Antiphospholipid antibodies and thrombosis: strength of association

Antiphospholipid syndrome: clinical and diagnostic utility of laboratory tests

Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group

Bleeding and thrombosis in acute leukemia: what does the future of therapy look like?

Chronic myeloproliferative disorders

Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study

Comments on pre-fibrotic myelofibrosis and how should it be managed

Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group

Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients

Efficacy and safety of low-dose aspirin in polycythemia vera

Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases.

European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 2012;97(3):360-5--comment

European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia.

Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group

Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study

Indications for lowering platelet numbers in essential thrombocythemia

Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3.

Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera

Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature

Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic review

Molecular characterization of a new recombination of the SIL/TAL-1 locus in a child with T-cell acute lymphoblastic leukaemia

Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management

Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management

Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.

Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.

Prevalence and risk factors for Pulmonary Hypertension associated with chronic Myeloproliferative Neoplasms

Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients.

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

Risk-adapted therapy in essential thrombocythemia and polycythemia vera

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.

Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study

Second cancers in MPN: Survival analysis from an international study

Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients

Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases

The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera

The European LeukemiaNet: achievements and perspectives

The haematocrit and platelet target in polycythemia vera

The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both?

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

Transplant-finalized salvage of adult acute lymphoblastic leukemia: results of a mitoxantrone- and methotrexate-based regimen in 36 patients

Treatment indications and choice of a platelet-lowering agent in essential thrombocythemia

What is the standard treatment in essential thrombocythemia

When and how to treat essential thrombocythemia